[ ] How venetoclax (ABT-199) targets and kills CLL cells

Published on

Topics include: Treatment | General

Dr William Wierda from the University of Texas MD Anderson Cancer Center, Houston, TX explains how the drug venetoclax (ABT-199) targets and kills chronic lymphocytic leukemia (CLL) cells. Venetoclax inhibits Bcl-2, which is present at high levels in CLL cells, and it is responsible for the prolonged survival of these cells. Venetoclax will block and decrease the activity of Bcl-2.

View more programs featuring

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on March 22, 2016